A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Phase 1 Completed 18 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.

Timeline

Start: 2024-04-29
Primary completion: 2025-09-16
Completion: 2025-09-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Repotrectinib	Small molecule	—	Oral

Indications

No indication recorded.